About Kolon Life Science
Kolon Life Science is a publicly listed company based in Seoul (South Korea) founded in 2006. Cell therapies, oncolytic viruses, and APIs are developed. The company has 444 employees. Its focus areas include Life Sciences, Cell Therapy, Stem Cells and Progenitor Cells.
Company details
Kolon Life Science was founded in 2006 in Seoul, South Korea. Operations focus on biopharmaceuticals, including the development of cell and gene therapeutics. INVOSSA-K injection, a cell suspension, is offered for treating moderate knee osteoarthritis. Oncolytic viruses are being developed for cancer and pain management. Active pharmaceutical ingredients, advanced intermediates, and antimicrobial agents are manufactured for applications in paints and cosmetics, alongside water solutions.
- Headquarters Seoul, South Korea
- Employees 444
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website kolonls.co.kr
- Social LinkedIn
- Legal Name Kolon Life Science Inc.
- Annual Revenue$144.7 M (USD)29.49as on Dec 31, 2025
- Net Profit$17.28 M (USD)as on Dec 31, 2025
- EBITDA$17.68 M (USD)as on Dec 31, 2025
- Employee Count444
IPO & Listings of Kolon Life Science
Kolon Life Science is a publicly listed company on the KRX with ticker symbol 102940 in South Korea, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Apr 2009
- Listed onKRX: 102940
- Listed entityKolon Life Science Inc.
- Exchange sectorProcess industries
- ISINKR7102940004
- Share price12,980.00 KRW · 2026-10-14
- Market capitalisation169,916,025,314.00 KRW
- Price to earnings5.2
- EPS (diluted, trailing year)2,477.73 KRW
- Volume (last session)64,701
Financials of Kolon Life Science
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 208.98B KRW | 24.96B KRW | 25.53B KRW |
| 2024 | 161.39B KRW | -93.09B KRW | -42.89B KRW |
| 2023 | 124.64B KRW | -30.73B KRW | -15.37B KRW |
| 2022 | 161.58B KRW | 2.13B KRW | 19.32B KRW |
| 2021 | 165.49B KRW | -1.37B KRW | 15.55B KRW |
Detailed financial statements for Kolon Life Science
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Kolon Life Science
The website of Kolon Life Science (kolonls.co.kr) receives about 4.6K visits a month and ranks #2,572,555 among all websites worldwide, #3,527 in Biotechnology and Pharmaceuticals.
- Monthly visits4.6K
▼ 43.7% vs previous month
- Unique visitors3.7K
per month
- Global rank#2,572,555
among all websites
- Category rank#3,527
Health · Biotechnology and Pharmaceuticals
- Bounce rate66%
- Pages per visit1.8
- Average visit30 sec
- DevicesDesktop 15% · Mobile 85%
Websites whose visitors overlap most with Kolon Life Science. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| kolonpharm.co.kr | 100% | #1,882,169 | View details | ||
| ckdbio.com | 86% | 4.6K | #3,295,379 | View details | |
yakup.com | yakup.com | 51% | #118,603 | – | |
medipana.com | medipana.com | 51% | #266,587 | – | |
| hitnews.co.kr | 51% | #146,502 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Kolon Life Science
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kolon Life Science
Complete news archive for Kolon Life Science
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kolon Life Science
Kolon Life Science was founded in 2006.
Kolon Life Science is headquartered in Seoul, South Korea.
Kolon Life Science has 444 employees.
Annual revenue of Kolon Life Science is $144.7M as on Dec 31, 2025.
Kolon Life Science was founded in 2006 in Seoul, South Korea. Operations focus on biopharmaceuticals, including the development of cell and gene therapeutics. INVOSSA-K injection, a cell suspension, is offered for treating moderate knee osteoarthritis. Oncolytic viruses are being developed for cancer and pain management. Active pharmaceutical ingredients, advanced intermediates, and antimicrobial agents are manufactured for applications in paints and cosmetics, alongside water solutions.
Yes, Kolon Life Science is publicly traded on KRX under the ticker symbol 102940.